We are seeking to build a team who share our vision and are passionate about the conversion of groundbreaking science into therapies.
The Milner Therapeutics Institute is part of the School of Biological Sciences and the School of Clinical Medicine at the University of Cambridge and is dedicated to the conversion of ground breaking science into therapies. It is currently based at the Gurdon Institute and will move into new purpose built drug discovery laboratories on the Cambridge Biomedical Campus in March 2019. The Institute is surrounded by a global therapeutic alliance of 74 SMEs, pharma companies, academic institutions and venture capital firms. The drug discovery research group at the Milner will be working on pre-competitive projects in collaboration with pharmaceutical companies and its own drug discovery portfolio.
Postdoctoral Scientist, Computational Biology
LifeArc and the Milner Therapeutics Institute set up a new partnership in 2018 to identify and validate new drug targets in immune-oncology and respiratory diseases. Under this new collaborative research projects, cutting-edge computational approaches, including artificial intelligence, machine learning, statistical and mathematical methods, are being developed and applied to pharmacogenomics and drug discovery processes to identify novel therapeutics targets, stratify patient populations and predict efficacy of new and existing drugs. Combining the drug discovery expertise of LifeArc with the machine learning and computational analysis expertise of the Milner Therapeutics Institute facilitates the identification and selection of novel targets for drug discovery.
We are seeking a postdoctoral scientist to work LifeArc-Milner collaborative projects. The post-holder will integrate, refine and analyse biological (multi-omics) data in order to identify, validate and prioritise novel drug targets, with a special focus on establishing disease associations.
Closing date: 28 January 2019